Featured News December 11, 2025Ophirex Announces Business Update: Advances Toward Food and Drug Administration (FDA) Approval for Varespladib as Novel Oral Snakebite TreatmentOphirex, Inc. announced a series of regulatory and business developments as it continues to advance varespladib as the first oral rescue treatment for snakebite envenomation. The company announced that the FDA agrees that development of varespladib for snakebite is appropriate under the FDA’s Animal Rule, which permits approval of drugs for human use using safety data from humans and efficacy data from well-controlled animal studies. Varespladib has also received FDA MUMS designation for treatment of snakebite in dogs.Press Releases Featured Media Load More
December 11, 2025Ophirex Announces Business Update: Advances Toward Food and Drug Administration (FDA) Approval for Varespladib as Novel Oral Snakebite TreatmentOphirex, Inc. announced a series of regulatory and business developments as it continues to advance varespladib as the first oral rescue treatment for snakebite envenomation. The company announced that the FDA agrees that development of varespladib for snakebite is appropriate under the FDA’s Animal Rule, which permits approval of drugs for human use using safety data from humans and efficacy data from well-controlled animal studies. Varespladib has also received FDA MUMS designation for treatment of snakebite in dogs.
